Marker Therapeutics Inc (OQ:MRKR)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4551 KENNEDY COMMERCE DR.
HOUSTON TX 77032
Tel: N/A
Website: https://markertherapeutics.com
IR: See website
<
Key People
Juan F. Vera
President, Chief Executive Officer, Principal Financial and Accounting Officer, Director 		Gerald Garrett
Vice President - Clinical Operations 		Nadia Agopyan
Vice President - Regulatory Affairs
Anna Szymanska
Vice President - Quality 		Tsvetelina P. Hoang
Vice President - Research and Development 		Monic Stuart
Chief Medical Officer
Business Overview
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Financial Overview
For the fiscal year ended 31 December 2023, Marker Therapeutics Inc revenues decreased 6% to $3.3M. Net loss before extraordinary items decreased 29% to $14M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 79% to $520K (expense), General and administrative - Balancing v decrease of 21% to $7M (expense).
Employees: 8 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $24.06M as of Dec 31, 2023
Annual revenue (TTM): $3.31M as of Dec 31, 2023
EBITDA (TTM): -$13.76M as of Dec 31, 2023
Net annual income (TTM): -$14.05M as of Dec 31, 2023
Free cash flow (TTM): -$16.55M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 8,902,897 as of Mar 18, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More